GlassScriptPhysician profile
Natasha Lin Burgert
NPI 1376583179
$19,650.70
in general payments reported to CMS, 2019-2025
9 companies · $5,919 in 2025
The $5,919 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,746 · 2020: $700 · 2021: $700 · 2022: $1,608 · 2023: $858 · 2024: $6,120 · 2025: $5,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,195 · Travel and Lodging: $2,847 · Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,195.00 |
| Travel and Lodging | $2,846.59 |
| Food and Beverage | $854.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19,444.97 | 2019-2025 | Varivax, Recombivax Hb, Enflonsia |
| Ironshore Pharmaceuticals INC. | $63.31 | 2019 | |
| Tris Pharma INC | $31.79 | 2019 | |
| Cranial Technologies, INC | $30.67 | 2019 | |
| Sanofi Pasteur INC. | $26.10 | 2019-2025 | |
| Kaleo, INC. | $15.64 | 2022 | |
| Shire North American Group INC | $13.98 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.31 | 2019 | |
| Adlon Therapeutics L.P. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Burgert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.